A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

StatusCompleted
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Results first posted: Jul 27, 2026v13 Show 4 more changesShow less
    • Primary endpoint revised
    • Start date: Mar 2007 to Feb 2007
    • Secondary endpoints revised (4)
    • Study sites revised (3)
  2. Study arms: 0 to 1v12
  3. Re-verified, no change to tracked fieldsv11
  4. Enrollment target: 15 to 10
    • Primary completion date: Dec 2009 to Feb 2008
    • Start date: Feb 2007 to Mar 2007
    v10
  5. 3 versions Re-verified since Sep 2, 2011, no change to tracked fieldsv7-v9
Show 5 earlier versionsHide 5 earlier versions
  1. Primary and study completion dates changed from estimate of Dec 2008 to Dec 2009
    • Trial status: Suspended to Completed
    v6
  2. Trial status: Recruiting to Suspended Sponsor's reason: Enrollment paused for interim data analyisv5 Show 5 more changesShow less
    • Primary completion date: Dec 2008
    • Study completion date: Jun 2008 to Dec 2008
    • Interventions: Recombinant vaccinia virus (TK-deletion plus GM-CSF) (Genetic) to JX-594 (Biological)
    • Secondary endpoints: details revised at 4 of 4 entries
    • Site details revised at 3 of 3 sites
  3. Study sites: 1 to 3
    • Study completion date: Apr 2008 to Jun 2008
    • Secondary endpoints: details revised at 1 of 4 entries
    v4
  4. Re-verified, no change to tracked fieldsv3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    • Study title shortened, about 2 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
Trial Details
NCT Number NCT00429312
Lead Sponsor Jennerex Biotherapeutics
Conditions
(from sponsor)		 Melanoma
Related terms Melanoma
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov